Sientra (NASDAQ:SIEN) Cut to Sell at StockNews.com

StockNews.com lowered shares of Sientra (NASDAQ:SIEN – Get Rating) from a hold rating to a sell rating in a research note released on Tuesday morning.

Several other brokerages also recently issued reports on SIEN. UBS Group decreased their target price on Sientra from $10.00 to $8.00 and set a buy rating on the stock in a research note on Tuesday, March 29th. Stifel Nicolaus reduced their price objective on shares of Sientra from $11.00 to $7.00 and set a buy rating on the stock in a research report on Thursday, March 24th. Lake Street Capital started coverage on shares of Sientra in a research report on Thursday, April 14th. They set a buy rating and a $8.00 target price for the company. Colliers Securities reiterated a buy rating on shares of Sientra in a report on Tuesday, March 22nd. Finally, Canaccord Genuity Group decreased their price target on shares of Sientra from $10.00 to $8.00 and set a buy rating on the stock in a research note on Tuesday, March 29th. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, Sientra presently has a consensus rating of Buy and an average target price of $7.75.

Shares of SIEN stock opened at $1.41 on Tuesday. The company has a market capitalization of $87.93 million, a price-to-earnings ratio of -0.82 and a beta of 2.11. Sientra has a one year low of $1.22 and a one year high of $9.14. The company’s fifty day moving average price is $2.02 and its 200-day moving average price is $3.18. The company has a debt-to-equity ratio of 1.53, a current ratio of 1.76 and a quick ratio of 1.10.

Sientra (NASDAQ:SIEN – Get Rating) last issued its quarterly earnings results on Wednesday, March 23rd. The medical instruments supplier reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.08). The business had revenue of $22.65 million during the quarter, compared to analysts’ expectations of $22.50 million. Sientra had a negative return on equity of 865.36% and a negative net margin of 112.89%. During the same quarter in the previous year, the company posted ($0.38) EPS. Equities research analysts expect that Sientra will post -0.88 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. Advisor Group Holdings Inc. increased its holdings in shares of Sientra by 230.9% in the 1st quarter. Advisor Group Holdings Inc. now owns 11,930 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 8,325 shares during the last quarter. Barclays PLC increased its holdings in shares of Sientra by 168.0% in the 4th quarter. Barclays PLC now owns 70,474 shares of the medical instruments supplier’s stock worth $259,000 after buying an additional 44,181 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Sientra by 1.8% in the 4th quarter. BlackRock Inc. now owns 3,693,642 shares of the medical instruments supplier’s stock worth $13,556,000 after buying an additional 66,003 shares during the last quarter. Paradigm Financial Partners LLC bought a new stake in shares of Sientra in the 4th quarter worth about $50,000. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Sientra by 190.5% in the 4th quarter. Goldman Sachs Group Inc. now owns 261,687 shares of the medical instruments supplier’s stock worth $961,000 after buying an additional 171,598 shares during the last quarter. Hedge funds and other institutional investors own 82.42% of the company’s stock.

About Sientra (Get Rating)

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Read More